Skip to content

Frontlight ResearchEarly access

Institution

Spitalul Clinic Colentina

Bucharest, RomaniaEU-13 widening countryWebsite

Also known as: Hospital Colentina

15running trials
13closed trials
2,455publications (OpenAlex)

Running trials

Recruiting
A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in Romania
NCT07582783· Janssen Research & Development, LLC· Source
Recruiting
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
NCT07186101· Phase 2· Eli Lilly and Company· Source
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
NCT07202884· Phase 3· Eli Lilly and Company· Source
Recruiting
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
NCT07136467· AbbVie· Source
Recruiting
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
NCT06937086· Phase 3· Eli Lilly and Company· Source
Recruiting
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
NCT06937099· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
NCT06056297· Phase 3· X4 Pharmaceuticals· Source
Active, not recruiting
Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.
NCT05930275· AbbVie· Source
Active, not recruiting
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease
NCT06107426· AbbVie· Source
Recruiting
Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency
NCT05879757· Takeda· Source
Active, not recruiting
Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease
NCT05043103· Britannia Pharmaceuticals Ltd.· Source
Active, not recruiting
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
NCT04562389· Phase 3· Karyopharm Therapeutics Inc· Source
Active, not recruiting
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
NCT04232553· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
NCT03519945· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Closed trials

Completed
Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension
NCT06153693· Phase 3· Mineralys Therapeutics Inc.· Source
Completed
Improvement of a Digital Health Platform for Remote Monitoring of Patients With Heart Failure
NCT05708846· humanITcare· Source
Completed
A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)
NCT05651711· Phase 3· Amgen· Source
Completed
A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review
NCT05444972· AbbVie· Source
Completed
Endoscopy and Radiology-guided Ablation for Inoperable Cholangiocarcinoma
NCT05563870· Clinical Hospital Colentina· Source
Terminated
The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis
NCT04985968· Phase 3· InDex Pharmaceuticals· Source
Completed
Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories
NCT04469686· Phase 3· Cristcot HCA LLC· Source
Completed
Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis
NCT03982394· AbbVie· Source
Completed
A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis
NCT03725202· Phase 3· AbbVie· Source
Completed
A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT03524092· Phase 3· Eli Lilly and Company· Source
Completed
An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
NCT03518086· Phase 3· Eli Lilly and Company· Source
Terminated
Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies
NCT02629692· Phase 1/2· Sun Pharma Advanced Research Company Limited· Source
Completed
A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease
NCT02620046· Phase 3· Takeda· Source

Registry name variants (23)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

Spitalul Clinic Colentina
Bucharest, 020125
18 trials
Colentina Hospital
Bucharest, 020125
1 trial
- NCT05708846Improvement of a Digital Health Platform for Remote Monitoring of Patients With Heart Failure
Colentina Hospital Bucharest
Bucharest, 020125
1 trial
- NCT05043103Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease
Gastroenterology Department, Colentina Hospital
Bucharest, 020125
1 trial
- NCT05563870Endoscopy and Radiology-guided Ablation for Inoperable Cholangiocarcinoma
Spitalul Clinic Colentina /ID# 204889
Bucharest, 020121
1 trial
- NCT03725202A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis
Spitalul Clinic Colentina /ID# 214307
Bucharest, 020121
1 trial
- NCT03982394Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis
Spitalul Clinic Colentina /ID# 224810
Bucharest, 020121
1 trial
- NCT03982394Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis
Spitalul Clinic Colentina /ID# 224811
Bucharest, 020121
1 trial
- NCT03982394Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis
Spitalul Clinic Colentina /ID# 245620
Bucharest, 020121
1 trial
- NCT05444972A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review
Spitalul Clinic Colentina /ID# 252250
Bucharest, 020121
1 trial
- NCT06107426Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease
Spitalul Clinic Colentina /ID# 260355
Bucharest, 020121
1 trial
- NCT05930275Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.
Spitalul Clinic Colentina /ID# 275506
Bucharest, Bucharest 020125
1 trial
- NCT07136467A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
  Contact: Beth Rycroft
Spitalul Clinic Colentina /ID# 275817
Bucharest, Bucharest 020125
1 trial
- NCT07136467A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
  Contact: Beth Rycroft
Spitalul Clinic Colentina Site 1
Bucharest, 020125
1 trial
- NCT06056297A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
  Contact: Patient Affairs and Advocacy
Spitalul Clinic Colentina Site 2
Bucharest, 020125
1 trial
- NCT06056297A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
  Contact: Patient Affairs and Advocacy
Spitalul Clinic Colentina - Dermatology II
Bucharest
Spitalul Clinic Colentina /ID# 205860
Bucharest, 020121
Spitalul Clinic Colentina /ID# 223680
Bucharest, 020121
Spitalul Clinic Colentina /ID# 263303
Bucharest, Bucharest 020125
Spitalul Clinic Colentina /ID# 267208
Bucharest, Bucharest 020125
Spitalul Clinic Colentina /ID# 275892
Bucharest, Bucharest 020125
Spitalul Clinic Colentina - parent
Bucharest, 020125
Spitalul Clinic Colentina
Bucharest, 020125

Conditions

Diseases this institution publishes on or runs trials for.

Systemic sclerosis (scleroderma)11 works · 0 trials

Institution data: ROR 04fkbqt11 (CC0-1.0)Updated 14 Nov 2026

Report an error

Spitalul Clinic Colentina: trials and research groups – Frontlight Research